EnteroMedics Inc  

(Public, NASDAQ:ETRM)   Watch this stock  
Find more results for ETRM
+0.003 (1.67%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.17 - 0.19
52 week 0.14 - 2.05
Open 0.18
Vol / Avg. 324,411.00/1.45M
Mkt cap 19.15M
P/E     -
Div/yield     -
EPS -0.33
Shares 106.40M
Beta 2.31
Inst. own 21%
Feb 16, 2016
Q4 2015 EnteroMedics Inc Earnings Release (Estimated) Add to calendar
Nov 19, 2015
EnteroMedics Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 9, 2015
Q3 2015 EnteroMedics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -6485.42% -
Operating margin -9391.22% -
EBITD margin - -
Return on average assets -145.43% -128.17%
Return on average equity -362.94% -244.84%
Employees 28 -
CDP Score - -


2800 Patton Rd
SAINT PAUL, MN 55113-1100
United States - Map
+1-651-6343003 (Phone)
+1-651-6343212 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.

Officers and directors

Mark B. Knudson Ph.D. Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Gregory S. Lea Chief Financial Officer, Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
Scott A. Shikora M.D. Executive Vice President - Medical Affairs and Chief Medical Officer
Bio & Compensation  - Reuters
Adrianus Donders Senior Vice President - Research and Advanced Development
Age: 61
Bio & Compensation  - Reuters
Katherine S. Tweden Ph.D. Senior Vice President - Research
Age: 54
Bio & Compensation  - Reuters
Tonya Dowd Vice President - Reimbursement
Bio & Compensation  - Reuters
Bradford C Hancock Chief Commercial Officer
Bio & Compensation  - Reuters
Anthony P. Jansz Director
Age: 54
Bio & Compensation  - Reuters
Lori Courtney McDougal Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 54
Bio & Compensation  - Reuters